EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

SGLT2 Inhibitors Mitigate Contrast-Induced Acute Kidney Injury in Diabetes: Clinical and Experimental Evidence

Mu-Chi Chung, Yu-Teng Chang iD, Yi-Jia Guo, Chi-Jung Chung, Laing-You Wu, Ming-Ju Wu iD, Jeng-Jer Shieh iD

International Journal of Molecular Sciences · 09.02.2026 · 27 (4) · 1684

DOI: 10.3390/ijms27041684 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 09.02.2026. Verfasst von Mu-Chi Chung und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine, Taichung Veterans General Hospital, Taichung 407219, Taiwan. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Acute Kidney Injury, Diabetes Mellitus, Type 2, Contrast Media. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Taichung Veterans General Hospital/National Chung Hsing University, the Taichung Veterans General Hospital/National Chung Hsing University Joint Research Program, the MOST Clinical Trial Consortium for Stroke.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Contrast-induced acute kidney injury (CIAKI) is a common complication after percutaneous coronary intervention (PCI) in type 2 diabetes mellitus (T2DM). The protective role of sodium-glucose co-transporter 2 inhibitors (SGLT2i) against CIAKI remains unclear. We aimed to evaluate the effects of SGLT2i using nationwide database analysis and experimental models. A nationwide nested case–control study using Taiwan’s National Health Insurance Research Database assessed the association between SGLT2i use and risk of post-PCI dialysis. Parallel in vitro experiments examined dapagliflozin in iopamidol-treated HK-2 cells, and in vivo studies tested dapagliflozin in diabetic rats exposed to iopamidol. Clinically, SGLT2i use significantly reduced the risk of post-PCI dialysis (adjusted OR 0.33, 95% CI 0.14–0.76; p = 0.0094). In vitro, dapagliflozin attenuated iopamidol-induced cytotoxicity and NLRP3 inflammasome activation in HK-2 cells. In diabetic rats, dapagliflozin improved renal function, reduced tubular injury, and suppressed inflammasome-driven inflammation. In conclusion, SGLT2i protect against CIAKI by mitigating tubular injury and inflammasome activation. These findings highlight their potential as a preventive strategy for CIAKI in T2DM patients undergoing PCI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsAcute Kidney InjuryDiabetes Mellitus, Type 2Contrast MediaBenzhydryl CompoundsGlucosidesDiabetes Mellitus, ExperimentalAnimalsHumansRatsMaleFemaleCase-Control StudiesMiddle AgedCell LineAgedSodium-Glucose Transporter 2

Stichwörter der Autor:innen

SGLT2 inhibitorsacute kidney injurycontrastdapagliflozintype 2 diabetes mellitus

Substanzen

Sodium-Glucose Transporter 2 InhibitorsContrast MediaBenzhydryl CompoundsGlucosidesdapagliflozinSodium-Glucose Transporter 2

Autor:innen und Institutionen

  • Division of Nephrology, Department of Medicine, Taichung Veterans General Hospital, Taichung 407219, Taiwan.
  • Ph.D. Program in Translational Medicine, National Chung Hsing University, Taichung 402204, Taiwan.
  • Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung 402204, Taiwan.
  • Division of Clinical Toxicology, Department of Medical Toxicology, Taichung Veterans General Hospital, Taichung 407219, Taiwan.
  • Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung 402204, Taiwan.
  • Department of Medical Research, Taichung Veterans General Hospital, Taichung 407219, Taiwan.

ORCID-Profile: Yu-Teng Chang, Ming-Ju Wu, Jeng-Jer Shieh

Förderung

  • Taichung Veterans General Hospital/National Chung Hsing University
  • the Taichung Veterans General Hospital/National Chung Hsing University Joint Research Program
  • the MOST Clinical Trial Consortium for Stroke
  • the Tseng-Lien Lin Foundation

Zitieren

APA

Chung, M. C., Chang, Y. T., Guo, Y. J., Chung, C. J., Wu, L. Y., Wu, M. J., & Shieh, J. J. (2026). SGLT2 Inhibitors Mitigate Contrast-Induced Acute Kidney Injury in Diabetes: Clinical and Experimental Evidence. International Journal of Molecular Sciences, 27(4), 1684. https://doi.org/10.3390/ijms27041684

Vancouver

Chung MC, Chang YT, Guo YJ, Chung CJ, Wu LY, Wu MJ, et al. SGLT2 Inhibitors Mitigate Contrast-Induced Acute Kidney Injury in Diabetes: Clinical and Experimental Evidence. International Journal of Molecular Sciences. 2026;27(4):1684. doi:10.3390/ijms27041684

BibTeX
@article{Chung2026,
  author = {Chung, Mu-Chi and Chang, Yu-Teng and Guo, Yi-Jia and Chung, Chi-Jung and Wu, Laing-You and Wu, Ming-Ju and Shieh, Jeng-Jer},
  title = {SGLT2 Inhibitors Mitigate Contrast-Induced Acute Kidney Injury in Diabetes: Clinical and Experimental Evidence},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {4},
  pages = {1684},
  doi = {10.3390/ijms27041684}
}
Kostenlos starten →